Sesen Bio, Inc. Banner Image

Sesen Bio, Inc. has reached its limit for free report views

Work for Sesen Bio, Inc.? Upgrade Your Profile and unlock all your annual reports.

Sesen Bio, Inc.

  • Ticker SESN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Sesen Bio, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicinium®, also known as VB4-845, is currently in a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submissionMore for Vicinium to the FDA under Rolling Review. Vicinium is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Sesen Bio, Inc.

Most Recent Annual Report

Sesen Bio, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Sesen Bio, Inc. has reached its limit for free report views.

Older/Archived Annual Reports